What question did this study set out to answer?

This research aims to evaluate if a new methylene blue formulation offers better clinical outcomes than a conventional formulation for initial pericoronitis.

May 9, 2026Clinical Oral Investigations0 citationsOpen Access

Comparing Antimicrobial Photodynamic Therapy for Treating Initial Pericoronitis

Comparison of antimicrobial photodynamic therapy protocols as adjunct treatment in the management of initial pericoronitis: a randomized, controlled, double-blind clinical trial

View Full Paper

Authors

TSTânia Oppido Schalch EAEllen Sayuri Ando‐Suguimoto BFBruno Souza Ferreira

Discussion

Member takes

Overview

Randomized trial compares two methylene blue formulations in initial pericoronitis, indicating no significant clinical superiority.

Key Points

This research aims to evaluate if a new methylene blue formulation offers better clinical outcomes than a conventional formulation for initial pericoronitis.
Randomized, controlled, double-blind clinical trial with 34 healthy young patients.
Participants were divided into two groups: one receiving conventional methylene blue and the other a new formulation.
Primary outcome was pain measured using the Visual Analog Scale, with assessments at baseline and four days post-treatment.
Both groups improved significantly in pain (G1: p = 0.022; G2: p = 0.001) and mouth opening (G1: p < 0.001; G2: p = 0.002).
No significant differences in final pain and mouth-opening outcomes between groups (p = 0.845 and p = 0.318, respectively).
Clinical outcomes showed no superiority of the new methylene blue formulation over the conventional one.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Schalch et al. (2026) studied this question.

synapsesocial.com/papers/69fecf71b9154b0b82876737 https://doi.org/10.1007/s00784-026-06898-5

Ask AI

Helpful

Bookmark

View Full Paper

May 9, 2026Clinical Oral Investigations0 citationsOpen Access

Comparing Antimicrobial Photodynamic Therapy for Treating Initial Pericoronitis

Comparison of antimicrobial photodynamic therapy protocols as adjunct treatment in the management of initial pericoronitis: a randomized, controlled, double-blind clinical trial

View Full Paper

Authors

TSTânia Oppido Schalch EAEllen Sayuri Ando‐Suguimoto BFBruno Souza Ferreira

Discussion

Member takes

Overview

Randomized trial compares two methylene blue formulations in initial pericoronitis, indicating no significant clinical superiority.

Key Points

This research aims to evaluate if a new methylene blue formulation offers better clinical outcomes than a conventional formulation for initial pericoronitis.
Randomized, controlled, double-blind clinical trial with 34 healthy young patients.
Participants were divided into two groups: one receiving conventional methylene blue and the other a new formulation.
Primary outcome was pain measured using the Visual Analog Scale, with assessments at baseline and four days post-treatment.
Both groups improved significantly in pain (G1: p = 0.022; G2: p = 0.001) and mouth opening (G1: p < 0.001; G2: p = 0.002).
No significant differences in final pain and mouth-opening outcomes between groups (p = 0.845 and p = 0.318, respectively).
Clinical outcomes showed no superiority of the new methylene blue formulation over the conventional one.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Schalch et al. (2026) studied this question.

synapsesocial.com/papers/69fecf71b9154b0b82876737 https://doi.org/10.1007/s00784-026-06898-5

Ask AI

Helpful

Bookmark

View Full Paper